Xencor posts Phase 2 data for vudalimab (PD1 x CTLA-4) in mCRPC

Xencor Inc

Additional clinical data from Phase 2 study of vudalimab monotherapy in metastatic castration-resistant prostate cancer posted on website.
Presentation includes vudalimab, a bispecific PD1 x CTLA-4 antibody, corporate overview.
No specific efficacy/safety figures provided in the filing; refer to full presentation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.